Renalytix (STU:2O9) Retained Earnings: €-148.01 Mil (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2O9 Renalytix PLC STU:2O9
12 GF Score
Price €0.07
GF Value €0.04
! 3 Warning Signs
View Full Analysis

What is Renalytix Retained Earnings?

Renalytix STU:2O9 +4.62% 12 Retained Earnings is €-148.01 Mil as of Dec. 2024. GuruFocus rates STU:2O9 with a GF Score™ of 12/100 and a GF Value™ of €0.04. The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Renalytix's retained earnings for the quarter that ended in Dec. 2024 was €-148.01 Mil.

Renalytix's quarterly retained earnings increased from Jun. 2024 (€-197.60 Mil) to Sep. 2024 (€-194.00 Mil) and increased from Sep. 2024 (€-194.00 Mil) to Dec. 2024 (€-148.01 Mil).

Renalytix's annual retained earnings increased from Jun. 2023 (€-163.45 Mil) to Jun. 2024 (€-135.01 Mil) but then declined from Jun. 2024 (€-135.01 Mil) to Jun. 2025 (€-140.65 Mil).


Renalytix  (STU:2O9) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Renalytix Retained Earnings Historical Data

* Premium members only.

The historical data trend for Renalytix's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renalytix Retained Earnings Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Retained Earnings
Get a 7-Day Free Trial -73.73 -126.95 -163.45 -135.01 -140.65

Renalytix Quarterly Data
Sep21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -178.30 -189.54 -197.60 -194.00 -148.01
STU:2O9
12GF Score
Renalytix PLC STU:2O9
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Renalytix Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-148.01 Mil mean?
Renalytix (STU:2O9) has a Retained Earnings of €-148.01 Mil as of Dec. 2024. Retained earnings is the amount of net income not issued to shareholders. View historical data on Renalytix and its competitors.
Is Renalytix's Retained Earnings too high?
Renalytix's current Retained Earnings is €-148.01 Mil. Overall, Renalytix has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Renalytix's Retained Earnings compare to VEEV and BTSG?
Renalytix's Retained Earnings of €-148.01 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Healthcare Providers & Services company?
A good Retained Earnings depends on the Healthcare Providers & Services industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Renalytix and its competitors. Renalytix's current Retained Earnings is €-148.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renalytix stock overvalued right now?
Renalytix (STU:2O9) has a current Retained Earnings of €-148.01 Mil. The stock's GF Value™ is €0.04, compared to a current price of €0.07 — trading 70% above its estimated fair value. The current Retained Earnings is €-148.01 Mil. Renalytix's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Renalytix (STU:2O9), the current Retained Earnings is €-148.01 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Renalytix (STU:2O9) Overvalued in 2026?

Based on GuruFocus' analysis, Renalytix stock appears to be overvalued. The current stock price of €0.07 is trading 70% above its estimated GF Value™ of €0.04.

Key valuation signals for STU:2O9:

  • Retained Earnings: €-148.01 Mil
  • GF Value™: €0.04 vs. price of €0.07 (70% above fair value)
  • GF Score™: 12/100 with 3 warning signs

No single metric tells the full story. See the STU:2O9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Renalytix Business Description

Other Exchanges RENXF:USARENX:UK2O9:Germany
Address 2 Leman Street, London, GBR, E1W 9US
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
12GF Score

Get the complete analysis for STU:2O9

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.04
GF Value